Introduction: Preimplantation gene diagnosis (PGD) is the process of biopsy and genetic analysis of artificially in vitro fertilized zygotes or blastocysts during the process of artificial assisted reproduction, from which genetically normal embryos are selected for transfer to obtain a healthy next generation, commonly known as third generation IVF. Pre-implantation diagnosis has been successfully implemented internationally for many single gene genetic disorders. The vast majority of hereditary deafness is a highly genetically heterogeneous single gene disorder and is eligible for clinical application of preimplantation diagnosis. For many families at risk of having a child with hereditary deafness, the only option before the advent of PGD technology was to prevent the birth of a child with hearing defects by prenatal diagnosis with amniotic membrane or amniotic fluid extraction at 11 to 22 weeks of gestation. In order to reduce the physical and psychological harm brought to the mother and family by repeated induction of labor, the Molecular Diagnostic Center for Deafness of PLA General Hospital has adopted the most advanced technology in the world to design preimplantation diagnosis methods for common deafness genes (GJB2, SLC26A4), established a clinical standardized process, and has successfully implemented the diagnosis. Suitable for: 1. Couples with deafness gene carriers who have been clearly diagnosed at our Deafness Molecular Diagnosis Center and wish to have a normal hearing next generation through IVF technology. 2.Healthy, no systemic diseases, no reproductive system diseases that are not suitable for IVF treatment. 3, have a certain understanding of the artificial assisted reproduction process, have reasonable expectations and good compliance. Technical advantages: 1. The Molecular Diagnostic Center for Deafness of PLA General Hospital is currently the only unit in China that can perform pre-implantation diagnosis of deafness genes 2. It can not only detect and avoid birth defects caused by common chromosomal abnormalities such as Down’s syndrome, but also screen and exclude embryos with complex chromosomal fragment deletions and duplications, avoid as much as possible post-implantation miscarriage and fetal abortion caused by chromosomal abnormalities, and improve implantation survival rate. 3. Using the most advanced international single-cell whole genome amplification technology to improve the homogeneity of amplified DNA products and avoid misdiagnosis caused by gene fragment loss. And through the SNP verification method to further ensure the correct diagnosis. 4. Our Reproductive Medicine Center has internationally advanced embryo biopsy, freezing and resuscitation technologies and rich experience in artificial assisted reproduction technology, which provides a reliable guarantee to improve the conception success rate of pre-implantation diagnosis.